Castration-resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy.
Atsuhi YanaseToru SugiharaTakahiro AkimotoHirotaka YokoyamaJun KameiAkira FujisakiSatoshi AndoTameto NaoiMitsuya MoritaTetsuya FujimuraPublished in: IJU case reports (2022)
Prostate cancer can occur even when leuprorelin is used for spinal and bulbar muscular atrophy; therefore, checking serum prostate-specific antigen to screen for prostate cancer before leuprorelin administration should be considered.